TITLE: Chairman of the Board
FUNDING AREAS: Science and health education and research throughout the United States; community wellness in certain parts of California, Kentucky, and Oregon
CONTACT: Visit PeopleFinder for email and phone number (paid subscribers only)
PROFILE: The Foundation's chairman is Richard Scheller, a scientist by trade and an executive vice president on the corporate side of Genentech.
His Bloomberg bio shares:
Dr. Richard H. Scheller, Ph.D. has been the Chief Science Officer and Head of Therapeutics at 23andMe, Inc. since March 12, 2015. Dr. Scheller is responsible for translating genetic information into the discovery and development of new therapies for both common and rare diseases. He serves as a Science Partner at The Column Group LLC. He has been an Adjunct Professor in the Department of Biochemistry and Biophysics at University of California, San Francisco since 2004. He served as a Professor of Molecular and Cellular Physiology and of Biological Sciences at Stanford University Medical Center from September 1982 to February 2001 and as an Investigator of the Howard Hughes Medical Institute from September 1990 to February 2001. He received his first academic appointment to Stanford University in 1982. Prior to 23andMe, he spent 14 years at Genentech, where he served in various research and development roles. He served as an Executive Vice President of Research & Early Development for Genentech, Inc. since September 2003. He was responsible for setting the strategy for Genentech's research and drug discovery activities. He served as the Head of Genentech Research & Early Development at Roche Holding AG from 2009 to December 31, 2014. He has nearly 20 years of leadership in drug discovery research and development. He served as the Chief Scientific Officer of Genentech, Inc. since June 2008 and also served as its Senior Vice President of Research from March 2001 to September 2003. He has been a Director of DiCE Molecules Corp. since May 11, 2016, ORIC Pharmaceuticals Inc. since December 2015, Xenon Pharmaceuticals Inc. since March 16, 2015 and Medrio, Inc. since November 2012. He serves as a Member of Scientific Advisory Board of Kallyope Inc. He serves as a Member of the Medical and Scientific Review Board of Evotec (US), Inc. In 2014, he was named a Trustee of Caltech. He served as a Member of Scientific Advisory Board of Intra-Cellular Therapies, Inc. and Rinat Neuroscience Corp. He served on numerous Advisory Boards including the National Advisory Mental Health Council of the National Institutes of Health. He served as the Chairman of the Genentech Foundation's board of directors. He has been a Director of Rafael Pharmaceuticals, Inc. since January 2017. He is a globally recognized leader in biomedical research. He has published over 200 papers in scientific journals and worked in cell biology. He has received several additional awards for his work elucidating the molecular mechanisms governing neurotransmitter release, including the 2013 Albert Lasker Basic Medical Research Award, the 2014 California Institute of Technology's Caltech Distinguished Alumni Award, the 2010 Kavli Prize in Neuroscience and the 1997 U.S. National Academy of Sciences Award in Molecular Biology. He has published more than 280 research studies. He is a Fellow of the American Academy of Arts and Sciences. He has published more than 200 primary research papers during his career. Dr. Scheller holds a B.S. in Biochemistry from the University of Wisconsin-Madison in 1975 and a Ph.D. in Chemistry from California Institute of Technology (Caltech) in 1980, where he was also a Postdoctoral Fellow, Division of Biology. He was also a Postdoctoral Fellow at Columbia University, College of Physicians & Surgeons.